Miguel Sena-Esteves
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Miguel Sena-Esteves has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Sabine Steffens
Institute for Cardiovascular Prevention (IPEK), University Hospital, LMU Munich, Munich, Germany
2 shared publications Alan Flake
The Children’s Hospital of Philadelphia
1 shared publicationAlan W. Flake
1 shared publicationAnat Stemmer-Rachamimov
Molecular Neuro-oncology Laboratory, Harvard Medical School, Boston, Massachusetts, USA
1 shared publicationC A Maguire
Department of Neurology, Massachusetts General Hospital, Charlestown, USA
1 shared publicationCasey A Maguire
Department of Neurology, Massachusetts General Hospital, and Neuroscience Program, Harvard Medical School, Boston, Massachusetts, USA
1 shared publication
Latest Publications
- Open Access
- 6 February 2009
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 16 (8) , 664-671
Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-β
Glioblastoma multiforme (GBM) is the most aggressive type of all primary brain tumors, with an overall median survival <1 year after diagnosis. Despite introduction of multimodal treatment approaches, the prognosis has not improved significantly over the past 50 years. In this study we investigated the effect of intracerebroventricular (ICV) injection of an adeno-associated virus (AAV) vector encoding human interferon-β (AAV-hIFN-β) on glioblastoma growth. Recently, we found that peritumoral parenchymal transduction with an AAV-hIFN-β was exceptionally efficient in eradicating GBM brain tumors. However, the extensive infiltration and migration displayed by glioblastoma cells in patients may leave a significant number of tumor cells outside a local therapeutic zone created by intraparenchymal delivery of AAV vectors. Here we show that pretreatment of mice by ICV infusion of an AAV-IFN-β completely prevents tumor growth in an orthotopic model of GBM. Furthermore, ICV infusion of AAV-IFN-β into mice bearing preestablished U87 intracranial tumors improved their survival compared to mice infused through the same route with a control AAV vector. These data suggest that ICV injection of AAV vectors encoding antitumor proteins is a promising approach deserving further consideration for the treatment of GBM.
- 6 February 2009
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 16 (8) , 664-671
Open AccessControlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-β
Glioblastoma multiforme (GBM) is the most aggressive type of all primary brain tumors, with an overall median survival <1 year after diagnosis. Despite introduction of multimodal treatment approaches, the prognosis has not improved significantly over the past 50 years. In this study we investigated the effect of intracerebroventricular (ICV) injection of an adeno-associated virus (AAV) vector encoding human interferon-β (AAV-hIFN-β) on glioblastoma growth. Recently, we found that peritumoral parenchymal transduction with an AAV-hIFN-β was exceptionally efficient in eradicating GBM brain tumors. However, the extensive infiltration and migration displayed by glioblastoma cells in patients may leave a significant number of tumor cells outside a local therapeutic zone created by intraparenchymal delivery of AAV vectors. Here we show that pretreatment of mice by ICV infusion of an AAV-IFN-β completely prevents tumor growth in an orthotopic model of GBM. Furthermore, ICV infusion of AAV-IFN-β into mice bearing preestablished U87 intracranial tumors improved their survival compared to mice infused through the same route with a control AAV vector. These data suggest that ICV injection of AAV vectors encoding antitumor proteins is a promising approach deserving further consideration for the treatment of GBM.
- Open Access
- 1 October 2008
- Published by Elsevier in Molecular Therapy
- Vol. 16 (10) , 1695-1702
Preventing Growth of Brain Tumors by Creating a Zone of Resistance
- 1 October 2008
- Published by Elsevier in Molecular Therapy
- Vol. 16 (10) , 1695-1702
Open AccessPreventing Growth of Brain Tumors by Creating a Zone of Resistance
- Open Access
- 1 January 2007
- Published by Elsevier in Molecular Therapy
- Vol. 15 (1) , 30-37
Complete Correction of Enzymatic Deficiency and Neurochemistry in the GM1-gangliosidosis Mouse Brain by Neonatal Adeno-associated Virus–mediated Gene Delivery
- 1 January 2007
- Published by Elsevier in Molecular Therapy
- Vol. 15 (1) , 30-37
Open AccessComplete Correction of Enzymatic Deficiency and Neurochemistry in the GM1-gangliosidosis Mouse Brain by Neonatal Adeno-associated Virus–mediated Gene Delivery
- 1 December 2004
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 70 (3) , 281-288
Transduction of human glial and neuronal tumor cells with different lentivirus vector pseudotypes
- 1 December 2004
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 70 (3) , 281-288
Transduction of human glial and neuronal tumor cells with different lentivirus vector pseudotypes
- 1 December 2004
- Published by Elsevier in Journal of Virological Methods
- Vol. 122 (2) , 131-139
Optimized large-scale production of high titer lentivirus vector pseudotypes
- 1 December 2004
- Published by Elsevier in Journal of Virological Methods
- Vol. 122 (2) , 131-139
Optimized large-scale production of high titer lentivirus vector pseudotypes